Strados Labs Remote Wearable in BI IPF Trial
Research has suggested that cough may be associated with worse outcomes in pulmonary fibrosis. Boehringer Ingelheim will assess how monitoring cough and crackles with the RESP Biosensor can be used to monitor the status of patients with this disease.
Boehringer Ingelheim will remotely monitor patients using Strados Labs’ FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF)
Read more
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Digital Measures of Health: What’s in it for Patients?April 8th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
